Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models

B. Lee, H. Lee, Y. R. Nam, J. H. Oh, Y. H. Cho, JinWoo Chang

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

In this study, we report the amelioration of parkinsonian symptoms in rat Parkinson's disease (PD) models, as a result of the expression of glutamate decarboxylase (GAD) 65 with a modified cytomegalovirus (CMV) promoter. The transfer of the gene for gamma-amino butryic acid (GAD), the rate-limiting enzyme in gama-amino butrylic acid (GABA) production, has been investigated as a means to increase inhibitory synaptic activity. Electrophysiological evidence suggests that the transfer of the GAD65 gene to the subthalamic nucleus (STN) can change the excitatory output of this nucleus to inhibitory output. Our in vitro results also demonstrated higher GAD65 expression in cells transfected with the JDK promoter, as compared to cells transfected with the CMV promoter. Also, a rat PD model in which recombinant adeno-associated virus-2 (rAAV2)-JDK-GAD65 was delivered into the STN exhibited significant behavioral improvements, as compared to the saline-injected group. Interestingly, we observed that these behavioral improvements were more obvious in rat PD models in which rAAV2-JDK-GAD65 was injected into the STN than in rat PD models in which rAAV2-CMV-GAD65 was injected into the STN. Moreover, according to electrophysiological data, the rAAV2-JDK-GAD65-injected group exhibited more constant improvements in firing rates than did the rAAV2-CMV-GAD65-injected group. These data indicate that the JDK promoter, when coupled with GAD65 expression, is more effective with regard to parkinsonian symptoms than is the CMV promoter.

Original languageEnglish
Pages (from-to)1215-1222
Number of pages8
JournalGene Therapy
Volume12
Issue number15
DOIs
Publication statusPublished - 2005 Aug 1

Fingerprint

Dependovirus
Glutamate Decarboxylase
Subthalamic Nucleus
Cytomegalovirus
Parkinson Disease
Amino Acids
Genes
Enzymes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Lee, B. ; Lee, H. ; Nam, Y. R. ; Oh, J. H. ; Cho, Y. H. ; Chang, JinWoo. / Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. In: Gene Therapy. 2005 ; Vol. 12, No. 15. pp. 1215-1222.
@article{e2e93318d95e496eadd4b8f1b063b043,
title = "Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models",
abstract = "In this study, we report the amelioration of parkinsonian symptoms in rat Parkinson's disease (PD) models, as a result of the expression of glutamate decarboxylase (GAD) 65 with a modified cytomegalovirus (CMV) promoter. The transfer of the gene for gamma-amino butryic acid (GAD), the rate-limiting enzyme in gama-amino butrylic acid (GABA) production, has been investigated as a means to increase inhibitory synaptic activity. Electrophysiological evidence suggests that the transfer of the GAD65 gene to the subthalamic nucleus (STN) can change the excitatory output of this nucleus to inhibitory output. Our in vitro results also demonstrated higher GAD65 expression in cells transfected with the JDK promoter, as compared to cells transfected with the CMV promoter. Also, a rat PD model in which recombinant adeno-associated virus-2 (rAAV2)-JDK-GAD65 was delivered into the STN exhibited significant behavioral improvements, as compared to the saline-injected group. Interestingly, we observed that these behavioral improvements were more obvious in rat PD models in which rAAV2-JDK-GAD65 was injected into the STN than in rat PD models in which rAAV2-CMV-GAD65 was injected into the STN. Moreover, according to electrophysiological data, the rAAV2-JDK-GAD65-injected group exhibited more constant improvements in firing rates than did the rAAV2-CMV-GAD65-injected group. These data indicate that the JDK promoter, when coupled with GAD65 expression, is more effective with regard to parkinsonian symptoms than is the CMV promoter.",
author = "B. Lee and H. Lee and Nam, {Y. R.} and Oh, {J. H.} and Cho, {Y. H.} and JinWoo Chang",
year = "2005",
month = "8",
day = "1",
doi = "10.1038/sj.gt.3302520",
language = "English",
volume = "12",
pages = "1215--1222",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "15",

}

Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. / Lee, B.; Lee, H.; Nam, Y. R.; Oh, J. H.; Cho, Y. H.; Chang, JinWoo.

In: Gene Therapy, Vol. 12, No. 15, 01.08.2005, p. 1215-1222.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models

AU - Lee, B.

AU - Lee, H.

AU - Nam, Y. R.

AU - Oh, J. H.

AU - Cho, Y. H.

AU - Chang, JinWoo

PY - 2005/8/1

Y1 - 2005/8/1

N2 - In this study, we report the amelioration of parkinsonian symptoms in rat Parkinson's disease (PD) models, as a result of the expression of glutamate decarboxylase (GAD) 65 with a modified cytomegalovirus (CMV) promoter. The transfer of the gene for gamma-amino butryic acid (GAD), the rate-limiting enzyme in gama-amino butrylic acid (GABA) production, has been investigated as a means to increase inhibitory synaptic activity. Electrophysiological evidence suggests that the transfer of the GAD65 gene to the subthalamic nucleus (STN) can change the excitatory output of this nucleus to inhibitory output. Our in vitro results also demonstrated higher GAD65 expression in cells transfected with the JDK promoter, as compared to cells transfected with the CMV promoter. Also, a rat PD model in which recombinant adeno-associated virus-2 (rAAV2)-JDK-GAD65 was delivered into the STN exhibited significant behavioral improvements, as compared to the saline-injected group. Interestingly, we observed that these behavioral improvements were more obvious in rat PD models in which rAAV2-JDK-GAD65 was injected into the STN than in rat PD models in which rAAV2-CMV-GAD65 was injected into the STN. Moreover, according to electrophysiological data, the rAAV2-JDK-GAD65-injected group exhibited more constant improvements in firing rates than did the rAAV2-CMV-GAD65-injected group. These data indicate that the JDK promoter, when coupled with GAD65 expression, is more effective with regard to parkinsonian symptoms than is the CMV promoter.

AB - In this study, we report the amelioration of parkinsonian symptoms in rat Parkinson's disease (PD) models, as a result of the expression of glutamate decarboxylase (GAD) 65 with a modified cytomegalovirus (CMV) promoter. The transfer of the gene for gamma-amino butryic acid (GAD), the rate-limiting enzyme in gama-amino butrylic acid (GABA) production, has been investigated as a means to increase inhibitory synaptic activity. Electrophysiological evidence suggests that the transfer of the GAD65 gene to the subthalamic nucleus (STN) can change the excitatory output of this nucleus to inhibitory output. Our in vitro results also demonstrated higher GAD65 expression in cells transfected with the JDK promoter, as compared to cells transfected with the CMV promoter. Also, a rat PD model in which recombinant adeno-associated virus-2 (rAAV2)-JDK-GAD65 was delivered into the STN exhibited significant behavioral improvements, as compared to the saline-injected group. Interestingly, we observed that these behavioral improvements were more obvious in rat PD models in which rAAV2-JDK-GAD65 was injected into the STN than in rat PD models in which rAAV2-CMV-GAD65 was injected into the STN. Moreover, according to electrophysiological data, the rAAV2-JDK-GAD65-injected group exhibited more constant improvements in firing rates than did the rAAV2-CMV-GAD65-injected group. These data indicate that the JDK promoter, when coupled with GAD65 expression, is more effective with regard to parkinsonian symptoms than is the CMV promoter.

UR - http://www.scopus.com/inward/record.url?scp=23744497262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744497262&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302520

DO - 10.1038/sj.gt.3302520

M3 - Article

VL - 12

SP - 1215

EP - 1222

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 15

ER -